Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Viridian Therapeutics, Inc., TG Therapeutics or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Viridian Therapeutics, Inc., TG Therapeutics and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Viridian Therapeutics, Inc., TG Therapeutics and Inc.

Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. The company’s product pipeline includes veligrotug, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R monoclonal antibodies targeting IGF-1R and engineered of half-life extension technology, which is in Phase 3 clinical trial for the treatment of TED. It also develops portfolio of engineered anti-neonatal Fc receptor inhibitors, such as VRDN-006 and VRDN-008 for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company’s development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. The company was incorporated in 1993 and is based in Morrisville, North Carolina.

Latest Biotechnology and Viridian Therapeutics, Inc., TG Therapeutics, Inc. Stock News

As of November 28, 2025, Viridian Therapeutics, Inc. had a $3.1 billion market capitalization, compared to the Biotechnology median of $222.5 million. Viridian Therapeutics, Inc.’s stock is up 66.7% in 2025, up 8.4% in the previous five trading days and up 51.97% in the past year.

Currently, Viridian Therapeutics, Inc. does not have a price-earnings ratio. Viridian Therapeutics, Inc.’s trailing 12-month revenue is $70.8 million with a -426.6% net profit margin. As of November 28, 2025, Viridian Therapeutics, Inc. has not reported significant year-over-year quarterly sales. Analysts expect adjusted earnings to reach $-3.532 per share for the current fiscal year. Viridian Therapeutics, Inc. does not currently pay a dividend.

As of November 28, 2025, TG Therapeutics, Inc. had a $4.9 billion market cap, putting it in the 69th percentile of all stocks. TG Therapeutics, Inc.’s stock is up 10.5% in 2025, up 9.2% in the previous five trading days and down 3.9% in the past year.

Currently, TG Therapeutics, Inc.’s price-earnings ratio is 12.0. TG Therapeutics, Inc.’s trailing 12-month revenue is $531.9 million with a 84.1% net profit margin. Year-over-year quarterly sales growth most recently was 92.7%. Analysts expect adjusted earnings to reach $2.875 per share for the current fiscal year. TG Therapeutics, Inc. does not currently pay a dividend.

How We Compare Viridian Therapeutics, Inc., TG Therapeutics and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Viridian Therapeutics, Inc., TG Therapeutics and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Viridian Therapeutics, Inc., TG Therapeutics and Inc. Stock Value Grades

Company	Ticker	Value
Viridian Therapeutics, Inc.	VRDN	F
TG Therapeutics, Inc.	TGTX	D

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Viridian Therapeutics, Inc. has a Value Score of 2, which is Ultra Expensive. TG Therapeutics, Inc. has a Value Score of 21, which is Expensive.

The Value Stock Winner: No Clear Winner

Neither Viridian Therapeutics, Inc., TG Therapeutics or Inc. has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if Viridian Therapeutics, Inc., TG Therapeutics or Inc. is the better investment when it comes to value.

Viridian Therapeutics, Inc., TG Therapeutics and Inc.’s Quality Grades

Company	Ticker	Quality
Viridian Therapeutics, Inc.	VRDN	F
TG Therapeutics, Inc.	TGTX	B

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

Viridian Therapeutics, Inc. has a Quality Score of 5, which is Very Weak. TG Therapeutics, Inc. has a Quality Score of 64, which is Strong.

The Quality Grade Winner: TG Therapeutics, Inc.

As you can clearly see from the Quality Grade breakdown above, TG Therapeutics, Inc. has a better overall quality grade than Viridian Therapeutics, Inc.. For investors who are looking for companies with higher quality than others in the same industry, TG Therapeutics, Inc. could be a good stock to add to their portfolios. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Viridian Therapeutics, Inc., TG Therapeutics and Inc.’s Momentum Grades

Company	Ticker	Momentum
Viridian Therapeutics, Inc.	VRDN	A
TG Therapeutics, Inc.	TGTX	C

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Viridian Therapeutics, Inc. has a Momentum Score of 91, which is Very Strong. TG Therapeutics, Inc. has a Momentum Score of 54, which is Average.

The Momentum Grade Winner: Viridian Therapeutics, Inc.

As you can clearly see from the Momentum Grade breakdown above, Viridian Therapeutics, Inc. is considered to have stronger momentum compared to TG Therapeutics, Inc.. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, Viridian Therapeutics, Inc. could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Viridian Therapeutics, Inc., TG Therapeutics and Inc. Grades

In addition to Value, Momentum and Quality, A+ Investor also provides grades for Growth and Estimate Revisions.

Earnings estimate revisions scores take into account the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, surprises beget further surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Viridian Therapeutics, Inc., TG Therapeutics and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Viridian Therapeutics, Inc., TG Therapeutics or Inc. Stock?

Overall, Viridian Therapeutics, Inc. stock has a Value Score of 2, Momentum Score of 91 and Quality Score of 5.

TG Therapeutics, Inc. stock has a Value Score of 21, Momentum Score of 54 and Quality Score of 64.

Comparing Viridian Therapeutics, Inc., TG Therapeutics and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.